Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68788-6806

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68788-6806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 01

This appears to be a table of drug interactions and recommendations for interacting with the drug Venlafaxine. The table includes information on which drugs (such as Ethanol, Diazepam, Cimetidine, and Ketoconazole) interact with Venlafaxine, and whether caution should be taken or the drugs should be avoided altogether. The table also includes PK fold change and 90% C recommendations for certain factors such as Cmax and AUC. Overall, this document seems to be a resource for medical professionals to consult when prescribing medications to patients who are taking Venlafaxine.*

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 02

This is a drug interaction chart that shows the potential interactions and recommendations for using different drugs. It includes drugs such as Diazepam, Alprazolam, Indinavir, Metoprolol, Risperidone, Imipramine, Haloperidol, Caffeine, and Lithium. The chart lists PKFold changes and recommendations for each analyte. The text also includes Cmax and Auc values for each drug and whether a dose adjustment is required or not. The chart shows whether concomitant use of these drugs should be avoided or used with caution, depending on the drug combination.*

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 03

This is a document related to pharmacokinetics and pharmacodynamics recommendations for a certain medication called Venlafaxine in patients with hepatic and renal impairments, cytochrome polymorphism, age, and gender. It provides dosage adjustments for patients with varying degrees of impairments and individualization of dosing when necessary. The document includes fold changes and 90% confidence intervals along with recommendations according to the patient's condition.*

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 04

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 07

Venlafexine HCl Extended Release Capsules are prescribed and contain Venlafusine hydrochloride. Each extended-release capsule contains 150mg of Venlafesine hydrochloride, which is equivalent to Venlafexine. It is important to note that it is illegal to transfer this medication without a prescription. Lot and product numbers are included.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.